Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects-Reference-Cited by-同舟云学术

Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects

Published:2009-02-24 Issue:6 Volume:65 Page:593-600
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Kodaira Chise,Sugimoto Mitsushige,Nishino Masafumi,Yamade Mihoko,Shirai Naohito,Uchida Shinya,Ikuma Mutsuhiro,Yamada Shizuo,Watanabe Hiroshi,Hishida Akira,Furuta Takahisa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-009-0625-8.pdf

Reference36 articles.

1. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252(3):1289–1295

2. Nagaya H, Inatomi N, Nohara A et al (1991) Effects of the enantiomers of lansoprazole (AG-1749) on (H++K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem Pharmacol 42(10):1875–1878

3. Blum RA (1996) Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm 53(12):1401–1415

4. Lockhart SP (1994) Clinical review of lansoprazole. Br J Clin Pract Suppl 75:48–55 discussion 56–57

5. Langtry HD, Wilde MI (1997) Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 54(3):473–500

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam;BMC Pediatrics;2024-07-19

2. Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders;Drug Metabolism and Pharmacokinetics;2024-07

3. Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics;Pharmaceutics;2024-04-02

4. A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps;Pharmacogenomics and Personalized Medicine;2023-06

5. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis;Gene Reports;2021-12